Click on headlines below to download research

Expanded R&D pipeline to fuel LT growth
AFT Pharmaceuticals | 29/04/2024

While AFT continues to gain commercial traction from Maxigesic/ Combogesic IV sales in the US (launched by partner Hikma in Q1 CY24) and anticipates the…

...read more

Poised for international market expansion
AFT Pharmaceuticals | 05/03/2024

AFT continues to focus on expanding its product portfolio and broadening its geographical footprint (including increased investments in its affiliates),…

...read more

US milestone triggers upside and guidance bump
AFT Pharmaceuticals | 19/02/2024

AFT Pharmaceuticals has announced the first sale of its intravenous pain relief medicine, Maxigesic IV, through its US licensing partner, Hikma Pharmaceuticals,…

...read more